Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy.
Efficacy
Field re-sting
HVA, hymenoptera venom allergy
Hymenoptera venom allergy
SR, systemic reaction
Safety
Systemic reaction
Tyrosine adsorbed
VIT, venom immunotherapy
Venom immunotherapy
t-VIT, tyrosine-adsorbed venom immunotherapy
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
12
07
2019
revised:
09
10
2019
accepted:
16
10
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
It is acknowledged that any claim of efficacy of allergen immunotherapy must be done for each specific product, and this remains true also for venom immunotherapy (VIT). Thus, we evaluated the efficacy and safety of a specific tyrosine-adsorbed VIT for Consecutive patients diagnosed with hymenoptera allergy, and receiving VIT for either A total of 247 patients (73 female) were observed (102 honeybee, group H, 145 vespula, group V). Seventy-five patients in group H had a re-sting, and 74/75 had a lower grade reaction at re-sting as compared to the pre-VIT reaction. Considering systemic reactions, protection was achieved in 89% of patients. In group V 118 patients were re-stung, and 76/118 patients with previous grade III-IV reaction had no more systemic reaction under VIT. Overall, considering systemic reactions, protection was achieved in 92% of subjects. Of note, in both groups there was a clear inverse correlation between the severity of pre-VIT and during VIT reactions. The duration of VIT at the time of re-sting did not affect the efficacy. The safety was overall good, with 18% ad 15.4% local reactions in groups H and V, respectively. Modified extracts, including tyrosine-absorbed, have the aim of improving the safety of VIT still yet maintaining the efficacy. Field re-sting is the best way to assess the efficacy in real life. In this observational study we could confirm the protective efficacy of the tyrosine-adsorbed extract, with a good safety expecially in the build-up using a modified-rush protocol. The tyrosine-adsorbed VIT used herein is a viable and advantageous form of treatment for hymenoptera allergy.
Identifiants
pubmed: 31768218
doi: 10.1016/j.waojou.2019.100086
pii: S1939-4551(19)31242-6
pii: 100086
pmc: PMC6872772
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100086Informations de copyright
© 2019 The Author(s).
Déclaration de conflit d'intérêts
None to declare for the present work.
Références
Allergy. 2019 Oct;74(10):1969-1976
pubmed: 31074868
Allergy. 2005 Dec;60(12):1459-70
pubmed: 16266376
Cochrane Database Syst Rev. 2012 Oct 17;10:CD008838
pubmed: 23076950
Allergy. 2004 Jun;59(6):589-95
pubmed: 15147443
World Allergy Organ J. 2018 Feb 2;11(1):3
pubmed: 29441146
Expert Rev Clin Immunol. 2015;11(8):877-84
pubmed: 26018865
J Asthma Res. 1966 Jun;3(4):331-3
pubmed: 4380730
Allergy Asthma Proc. 2006 Mar-Apr;27(2):151-8
pubmed: 16724636
Allergol Immunopathol (Madr). 1995 Nov-Dec;23(6):277-84
pubmed: 8579006
J Allergy Clin Immunol. 2012 Jul;130(1):162-8
pubmed: 22460067
Allergy. 2009 Aug;64(8):1229-30
pubmed: 19416139
Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):330-6
pubmed: 20410817
Allergy. 2018 Apr;73(4):744-764
pubmed: 28748641
World Allergy Organ J. 2015 Sep 16;8(1):29
pubmed: 26417398
Ann Allergy Asthma Immunol. 2006 Jul;97(1):92-7
pubmed: 16892788
J Allergy Clin Immunol. 1992 Sep;90(3 Pt 1):335-9
pubmed: 1345753
J Investig Allergol Clin Immunol. 2019;29(3):180-205
pubmed: 30183660
Ann Allergy Asthma Immunol. 2013 Jan;110(1):51-4
pubmed: 23244659
Ann Allergy Asthma Immunol. 2017 Jan;118(1):28-54
pubmed: 28007086